Medications

Origin of resistance to lung-cancer drug discovered

Researchers at Kanazawa University report in Nature Communications that AXL, a protein belonging to the class of receptor tyrosine kinases, causes some lung cancer patients to have an intrinsic resistance to the drug osimertinib. ...

Cancer

FDA approves iressa for EGFR metastatic lung cancer

(HealthDay)—Iressa (gefitinib) has been approved by the U.S. Food and Drug Administration to treat patients with metastatic non-small-cell lung cancer (NSCLC) with a specific genetic mutation (epidermal growth factor receptor ...

Cancer

Drug-resistant lung cancer may have Achilles heel

Drugs introduced more than a decade ago that target mutations in a protein known as the epidermal growth factor receptor (EGFR) held the promise of personalized treatments for a common form of non-small cell lung cancer. ...

page 1 from 9